Sanjay Goel, MD, MS

home / authors / sanjay-goel-md-ms

Articles

Sanjay Goel, MD, MS

Dr Goel on the Safety Profile of Tinengotinib in Solid Tumors

Sanjay Goel, MD, MS
September 1st 2023

Sanjay Goel, MD, MS, discusses the safety profile of the TKI tinengotinib as a monotherapy and in combination with chemotherapy in patients with solid tumors.

Read More

Sanjay Goel, MD, MS

Dr Goel on the Mechanism of Action of Tinengotinib in Solid Tumors

Sanjay Goel, MD, MS
August 30th 2023

Sanjay Goel, MD, MS, discusses the mechanism of action of tinengotinib and the efficacy of this agent in patients with cholangiocarcinoma.

Read More

Sanjay Goel, MD, MS

Dr Goel on the Preliminary Efficacy of Tinengotinib Monotherapy in Advanced Solid Tumors

Sanjay Goel, MD, MS
June 13th 2023

Sanjay Goel, MD, MS, discusses the preliminary efficacy of tinengotinib monotherapy in advanced solid tumors according to data from a phase 1b/2 trial (NCT04742959).

Read More

Sanjay Goel, MD, MS

Dr. Goel on the Evolution of Precision and Personalized Medicine in Cancer Care

Sanjay Goel, MD, MS
February 16th 2023

Sanjay Goel, MD, MS, discusses the evolution of precision and personalized medicine in cancer care.

Read More

Sanjay Goel, MD, MS

Dr. Goel on the Need for Diverse Representation in Clinical Trials

Sanjay Goel, MD, MS
May 26th 2022

Sanjay Goel, MD, MS, discusses the need for diverse representation in clinical trials.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data